



Please type a plus sign (+) inside this box → +

AUG 17 2001

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/21 (6-98)

Approved for use through 09/30/2000. OBM 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

|                        |               |
|------------------------|---------------|
| Application Number     | 09/834,596    |
| Filing Date            | 13 April 2001 |
| First Named Inventor   | WATANABE      |
| Group Art Unit         | 1614          |
| Examiner Name          | Not Assigned  |
| Attorney Docket Number | PHARM1        |

AUG 21 2001  
CENTER 16002900  
RECEIVED

## ENCLOSURES (check all that apply)

|  |   |  |
|--|---|--|
| <input type="checkbox"/> Fee Transmittal Form                                    | <input type="checkbox"/> Assignment Papers<br><i>(for an Application)</i>               | <input type="checkbox"/> After Allowance Communication to Group                                      |
| <input type="checkbox"/> Fee Attached  | <input type="checkbox"/> Drawing(s) 4 sheets  | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences                  |
| <input type="checkbox"/> Amendment/Response                                      | <input type="checkbox"/> Licensing-related Papers                                       | <input type="checkbox"/> Appeal Communication to Group<br><i>(Appeal Notice, Brief, Reply Brief)</i> |
| <input type="checkbox"/> After Final   | <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition    | <input type="checkbox"/> Proprietary Information   |
| <input type="checkbox"/> Affidavits/declaration(s)                               | <input type="checkbox"/> Petition to Convert to a Provisional Application               | <input type="checkbox"/> Status Letter   |
| <input type="checkbox"/> Extension of Time Request; 1 mo.                        | <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address | <input checked="" type="checkbox"/> Additional Enclosure(s)<br><i>(please identify below):</i>       |
| <input type="checkbox"/> Express Abandonment Request                             | <input type="checkbox"/> Terminal Disclaimer  | <input type="checkbox"/> Return Receipt Postcard PTO-1449  |
| <input checked="" type="checkbox"/> Information Disclosure Statement             | <input type="checkbox"/> Small Entity Statement   | <input type="checkbox"/> Copies of References Cited  |
| <input type="checkbox"/> Certified Copy of Priority Document(s)                  | <input type="checkbox"/> Request for Refund   |  |
| <input type="checkbox"/> Response to Missing Parts/ Incomplete Application       |   |  |
| <input type="checkbox"/> Response to Missing Parts under 37 C.F.R § 1.52 or 1.53 |   |  |

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

|                         |   |
|-------------------------|---|
| Firm or Individual name | Jacqueline Haley, Registration No. 41,457 |
| Signature               |   |
| Date                    | 15 August 2001                            |

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 15 August 2001

|                       |                  |      |                 |
|-----------------------|------------------|------|-----------------|
| Typed or printed name | Jacqueline Haley |      |                 |
| Signature             |                  | Date | August 15, 2001 |

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Patent  
Customer No.: 006980  
Docket No.: PHARM1

TECH CENTER 1600/2900

AUG 21 2001

RECEIVED

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of )  
WATANABE, K., et al. ) Group Art Unit: 1614  
Serial No.: 09/834,596 ) Examiner: Not Assigned  
Filed: 13 April 2001 )  
For: **3' OR 2'-HYDROXYMEHTYL** )  
**SUBSTITUTED NUCLEOSIDE** )  
**DERIVATIVES FOR THE** )  
**TREATMENT OF HEPATITIS** )  
**VIRUS INFECTIONS** )

**INFORMATION DISCLOSURE STATEMENT**

Honorable Assistant Commissioner of  
Patents  
Washington, D.C. 20231

Atlanta, Georgia 30308-2216

Dear Sir:

In accordance with the continuing duty under 37 C.F.R. §1.56 to disclose to the United States Patent and Trademark Office any information that may be material to the patentability of the above-identified invention, enclosed please find form PTO 1449 listing references presently known to Applicants relating to the above-identified application. Also enclosed are copies of the cited references. The submission of this information shall not be deemed an admission that this information is necessarily material to the patentability of the above-identified application.

This information disclosure statement is being submitted prior to the mailing of a first Office Action on the merits. Therefore, Applicants believe that no fee is due under 37 C.F.R. §1.17.

The Commissioner is hereby authorized to charge any deficiency in fees or credit any overpayment to PTO Deposit Account No. 20-1507.


Respectfully submitted,

  
Jacqueline Haley  
Registration No. 41,457

I hereby certify that this correspondence is being deposited with the United States Postal Service with appropriate first class postage in an envelope addressed to: Honorable Assistant Commissioner of Patents, Washington, D.C. 20231 on 8-15-01

Jacqueline Haley, Reg. No. 41,457

Name of Registered Representative



Signature

8-15-01

Date

TROUTMAN SANDERS LLP  
Bank of America Plaza, Suite 5200  
600 Peachtree Street, N.E.  
Atlanta, Georgia 30308-2216  
404.885-3561

Please type a plus sign (+) inside this box →  +

AUG 17 2001

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OBM 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

|  |   |  |   |
|--|---|--|---|
| <p><b>Substitute for form 1449A/PTO</b></p> <p><b>INFORMATION DISCLOSURE</b></p> <p><b>STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p> |   | <p>Application Number      09/834,596</p> <p>Filing Date      13 April 2001</p> <p>First Named Inventor      Watanabe, K.</p> <p>Group Art Unit      1614</p> <p>Examiner Name      Not Assigned</p> <p>Attorney Docket Number      PHARM1</p> |   |
| Sheet  | 1 | of   | 3 |

RECEIVED

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**


|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the twoletter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement.** This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OBM 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

|                                   |   |                        |              |
|-----------------------------------|---|------------------------|--------------|
| Substitute for form 1449B/PTO     |   | Application Number     | 09/834,596   |
| INFORMATION DISCLOSURE            |   | Filing Date            | 04/13/01     |
| STATEMENT BY APPLICANT            |   | First Named Inventor   | WATANABE     |
| (use as many sheets as necessary) |   | Group Art Unit         | 1614         |
| Sheet                             | 2 | of                     | 3            |
|                                   |   | Examiner Name          | Not Assigned |
|                                   |   | Attorney Docket Number | PHARM1       |

+ AUG 21 2001

RECEIVED  
TECH CENTER 1000/2000

#### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials <sup>1</sup> | Code No. <sup>2</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, paper(s), volume-issue number(s), publisher, city and/or county where published. | T <sup>3</sup> |
|--------------------------------|-----------------------|---|----------------|
|                                |                       | Fedorov, I., et al., XIII International Round Table: Nucleosides, Nucleotides and Their Biological Applications. Montpellier, France, September 6-10, 1998. Poster 35.  |                |
|                                |                       | Kato, K., et al., XIII International Round Table: Nucleosides, Nucleotides and Their Biological Applications. Montpellier, France, September 6-10, 1998. Poster 49.   |                |
|                                |                       | Svansson, L., et al., J. Org. Chem., 1991, 56: 2993-97  |                |
|                                |                       | Wengel, J., et al., Bioorganic & Medicinal Chemistry, vol. 3, No. 9, pp. 1223-29, 1995.   |                |
|                                |                       | Lin, T., et al., J. Med. Chem., 1993, 36:353-62   |                |
|                                |                       | Gauvry, N., et al., Tetrahedron 55 (1999) 1321-28.  |                |
|                                |                       | Sterzyncki, R., et al., Nucleosides & Nucleotides, 10(1-3), 291-94 (1991)   |                |
|                                |                       | Lee-Ruff, E., et al., J. Med. Chem., 1996, 39:5276-80   |                |
|                                |                       | Bamford, M., et al., J. Med. Chem., 1990, 33:2494-2501  |                |
|                                |                       | Tino, J., J. Med. Chem., 1993, 36:1221-29   |                |
|                                |                       | Brown, B., J. Org. Chem., 1998, 63:8012-18  |                |


|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the twoletter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



PTO/SB/088 (10-96)

Approved for use through 10/31/99. OMB 9651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

AUG  
2001  
RECEIVED

|                                   |   |                        |              |
|-----------------------------------|---|------------------------|--------------|
| Substitute for form 1449B/PTO     |   | Application Number     | 09/834,596   |
| INFORMATION DISCLOSURE            |   | Filing Date            | 04/13/01     |
| STATEMENT BY APPLICANT            |   | First Named Inventor   | WATANABE     |
| (use as many sheets as necessary) |   | Group Art Unit         | 1614         |
| Sheet                             | 3 | of                     | 3            |
|                                   |   | Examiner Name          | Not Assigned |
|                                   |   | Attorney Docket Number | PHARM1       |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS |                       |   |
|---|-----------------------|---|
| Examiner Initials <sup>1</sup>                    | Code No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, paper(s), volume-issue number(s), publisher, city and/or county where published. |
|   |                       | Pudlo, J., Nucleosides & Nucleotides, 11(2-4), 279-93 (1992)  |
|   |                       | Fiandor, J., et al., Nucleosides & Nucleotides, 8(5&6), 1107-8 (1989)   |
|   |                       | Jeong, L., et al., Nucleosides & Nucleotides, 16(7-9), 1059-62 (1997)   |
|   |                       | Jorgensen, P., et al., Nucleosides & Nucleotides, 16(7-9), 1063-66 (1997)   |
|   |                       | Frieden, M., et al., J. Chem. Soc. Perkin Trans I, 1998, 2827-32  |
|   |                       | Slusarchyk, W., J. Med. Chem., 1992, 35:1799-1806   |
|   |                       | Bisacchi, G., et al., J. Med. Chem., 1991, 34:1415-21   |
|   |                       | Qiu, Y., et al., J. Med. Chem., 1998, 41:10-23  |
|   |                       | Sekiyama, T., J. Med. Chem., 1998, 41:1284-98   |
|   |                       |   |
|   |                       |   |
|   |                       |   |
|   |                       |   |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the twoletter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.